197 related articles for article (PubMed ID: 23721329)
1. T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.
Burman J; Fransson M; Tötterman TH; Fagius J; Mangsbo SM; Loskog AS
Immunology; 2013 Oct; 140(2):211-9. PubMed ID: 23721329
[TBL] [Abstract][Full Text] [Related]
2. Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens.
Rodi M; Dimisianos N; de Lastic AL; Sakellaraki P; Deraos G; Matsoukas J; Papathanasopoulos P; Mouzaki A
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27571060
[TBL] [Abstract][Full Text] [Related]
3. A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature.
Das J; Gill A; Lo C; Chan-Lam N; Price S; Wharton SB; Jessop H; Sharrack B; Snowden JA
Front Immunol; 2020; 11():668. PubMed ID: 32431694
[TBL] [Abstract][Full Text] [Related]
4. T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention.
van Langelaar J; van der Vuurst de Vries RM; Janssen M; Wierenga-Wolf AF; Spilt IM; Siepman TA; Dankers W; Verjans GMGM; de Vries HE; Lubberts E; Hintzen RQ; van Luijn MM
Brain; 2018 May; 141(5):1334-1349. PubMed ID: 29659729
[TBL] [Abstract][Full Text] [Related]
5. The T-cell pool is anergized in patients with multiple sclerosis in remission.
Fransson ME; Liljenfeldt LS; Fagius J; Tötterman TH; Loskog AS
Immunology; 2009 Jan; 126(1):92-101. PubMed ID: 18624727
[TBL] [Abstract][Full Text] [Related]
6. Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis.
Darlington PJ; Stopnicki B; Touil T; Doucet JS; Fawaz L; Roberts ME; Boivin MN; Arbour N; Freedman MS; Atkins HL; Bar-Or A
Front Immunol; 2018; 9():834. PubMed ID: 29867923
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment.
Nguyen Ky M; Duran A; Hasantari I; Bru A; Deloire M; Brochet B; Ruet A; Schmitt N
Neurol Neuroimmunol Neuroinflamm; 2023 Nov; 10(6):. PubMed ID: 37739811
[TBL] [Abstract][Full Text] [Related]
8. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation.
Darlington PJ; Touil T; Doucet JS; Gaucher D; Zeidan J; Gauchat D; Corsini R; Kim HJ; Duddy M; Jalili F; Arbour N; Kebir H; Chen J; Arnold DL; Bowman M; Antel J; Prat A; Freedman MS; Atkins H; Sekaly R; Cheynier R; Bar-Or A;
Ann Neurol; 2013 Mar; 73(3):341-54. PubMed ID: 23463494
[TBL] [Abstract][Full Text] [Related]
9. Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis.
Meira M; Sievers C; Hoffmann F; Rasenack M; Kuhle J; Derfuss T; Kappos L; Lindberg RL
J Immunol Res; 2014; 2014():897249. PubMed ID: 24901013
[TBL] [Abstract][Full Text] [Related]
10. The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies.
Amoriello R; Greiff V; Aldinucci A; Bonechi E; Carnasciali A; Peruzzi B; Repice AM; Mariottini A; Saccardi R; Mazzanti B; Massacesi L; Ballerini C
Front Immunol; 2020; 11():559. PubMed ID: 32328061
[TBL] [Abstract][Full Text] [Related]
11. Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism.
Ramos-Cejudo J; Oreja-Guevara C; Stark Aroeira L; Rodriguez de Antonio L; Chamorro B; Diez-Tejedor E
J Clin Immunol; 2011 Aug; 31(4):623-31. PubMed ID: 21491095
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantation.
Capobianco M; Motuzova Y; Frau J; Cocco E; Mamusa E; Marrosu MG; Bertolotto A
Neurol Sci; 2012 Aug; 33(4):863-7. PubMed ID: 22116203
[TBL] [Abstract][Full Text] [Related]
13. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
[TBL] [Abstract][Full Text] [Related]
14. miR-27a and miR-214 exert opposite regulatory roles in Th17 differentiation via mediating different signaling pathways in peripheral blood CD4+ T lymphocytes of patients with relapsing-remitting multiple sclerosis.
Ahmadian-Elmi M; Bidmeshki Pour A; Naghavian R; Ghaedi K; Tanhaei S; Izadi T; Nasr-Esfahani MH
Immunogenetics; 2016 Jan; 68(1):43-54. PubMed ID: 26563334
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional characteristics of CD4+ T cells in multiple sclerosis: relative lack of suppressive populations in blood.
Edström M; Mellergård J; Mjösberg J; Jenmalm M; Vrethem M; Press R; Dahle C; Ernerudh J
Mult Scler; 2011 Jan; 17(1):57-66. PubMed ID: 20847001
[TBL] [Abstract][Full Text] [Related]
16. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis.
Kaufman M; Pardo G; Rossman H; Sweetser MT; Forrestal F; Duda P
J Neurol Sci; 2014 Jun; 341(1-2):22-7. PubMed ID: 24731783
[TBL] [Abstract][Full Text] [Related]
17. Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party.
Cencioni MT; Genchi A; Brittain G; de Silva TI; Sharrack B; Snowden JA; Alexander T; Greco R; Muraro PA
Front Immunol; 2021; 12():813957. PubMed ID: 35178046
[TBL] [Abstract][Full Text] [Related]
18. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.
Abrahamsson SV; Angelini DF; Dubinsky AN; Morel E; Oh U; Jones JL; Carassiti D; Reynolds R; Salvetti M; Calabresi PA; Coles AJ; Battistini L; Martin R; Burt RK; Muraro PA
Brain; 2013 Sep; 136(Pt 9):2888-903. PubMed ID: 23864273
[TBL] [Abstract][Full Text] [Related]
19. Recognition of viral and self-antigens by T
Paroni M; Maltese V; De Simone M; Ranzani V; Larghi P; Fenoglio C; Pietroboni AM; De Riz MA; Crosti MC; Maglie S; Moro M; Caprioli F; Rossi R; Rossetti G; Galimberti D; Pagani M; Scarpini E; Abrignani S; Geginat J
J Allergy Clin Immunol; 2017 Sep; 140(3):797-808. PubMed ID: 28237728
[TBL] [Abstract][Full Text] [Related]
20. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
